Tempus AI TEM posted another breakout quarter as diagnostics volumes and pricing improved while data partnerships extended ...

Tempus AI is using the power of artificial intelligence to improve patient care. After holding its IPO in June 2024, Tempus AI stock has experienced some significant price swings. Despite its rise ...

Tempus AI grew revenue 30.4% YoY in FY2024 to $693.4M, with Q4 growth at 35.8%. Genomics drove 65% of FY2024 revenue at $451.7M with a suboptimal 49.2% gross margin and cost-intensive delivery. Data & ...

Tempus AI TEM operates at the intersection of clinical genomics and AI-driven insights. Its testing and data products are ...

Tempus AI Inc (NASDAQ:TEM) shares are trading lower by 1.7% to $53.15 Tuesday afternoon. The company will report its first-quarter earnings after Tuesday's market close, with analysts expecting a loss ...

Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; ...

If you are trying to decide what to do with your Tempus AI shares, or if you are watching the fast-moving world of AI stocks for the next big winner, it is time for a closer look. Tempus AI stock has ...

* Lacks grab-you-by-the-throat good looks (but would probably look at home in any room in the house) If you're a radio person while at home and are in the market for something better than the ...

Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in their positions. While strong enthusiasm for artificial intelligence (AI) ...